COMPANY PROFILE

DiogenX

Explore full profile

Beta-Cell recovery to counter diabetes

Marseille, FranceFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About DiogenX

Developer of therapeutic services intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of type 1 and type 2 diabetes by developing a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, enabling patients to get benefits in terms of quality of life and survival. Keywords: Pharmaceuticals and Biotechnology, Autoimmune Disorder, Beta-Cell Recovery, Cell System, Diabetic Patient, Pancreatic Beta-Cells, Peripheral Target.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Marseille, France
Employees: 24
Open positions: None listed
Dealroom signal: 88.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Diabetes, Biotechnology, Spinout, EIC, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe, observatoire industrial tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2023	$6.6M	$151M	Sunstone Life Science Ventures	↗
SERIES A✓Equity / VC	May 2023	$30M	$121M	Boehringer Ingelheim Venture Fund · Omnes Capital · Roche Venture Fund · JDRF T1D Fund	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

DiogenX website traffic

Latest recorded traffic for DiogenX is 1.2K monthly website visits, up 192.7% over the last three months. DiogenX's team grew 9.1% over the past year.

Latest monthly visits1.2K 3-month web change+192.7% 1-year team growth+9.1%

Monthly website visitsSep 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational	29	$18M	$53M
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational
ATApmonia TherapeuticsApmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies	Reims, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
QFQfluidicsDevelops low shear technologies based on its patented technology of liquid tube to offer innovative equipment dedicated to the biotechnology and biopharmaceutical production	Strasbourg, France	Operational
TTTreeFrog TherapeuticsStem cell company that will enable millions of patients to access the medical revolution of cell	Pessac, France	Operational
STStimunityTurn cancer immunotherapies active in most patient	Paris, France	Operational